Clinical Trials Logo

Pmm2-CDG clinical trials

View clinical trials related to Pmm2-CDG.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05549219 Recruiting - Pmm2-CDG Clinical Trials

24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG

Start date: November 29, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase 2, randomized, open-label, 24-week treatment study to evaluate the potential pharmacodynamic (PD) activity, safety, tolerability, and pharmacokinetics (PK) of GLM101 in adult, adolescent, and pediatric, patients with a confirmed diagnosis of PMM2-CDG. The planned doses of GLM101 to be investigated are 10, 20 and 30 mg/kg. The study will consist of a Screening Period, a 24-week (6-month) Treatment Period, and a 30-day (1-month) Follow-Up Period.